Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors
Abstract
Objectives: Human Epididymal Secretory Protein 4 was firstly described as an epididymis-specific protein but more recently it has been demonstrated to be a putative serum tumor marker for different malignancies, especially ovarian epithelial cancers. The aim of this study is to investigate the association between tissue Human Epididymal Secretory Protein 4 expression and the clinicopathological features of uterine cervical tumors.
Material and methods: This retrospective study was designed to evaluate the differences of tissue expressions of Human Epididymal Secretory Protein 4 protein in a spectrum of cervical neoplasms. One hundred and seven patients recently diagnosed as having cervical intraepithelial neoplasm or invasive squamous cell carcinoma, adenosquamous carcinoma and adenocarcinoma based on pathology databases.
Results: Decreased or negative Human Epididymal Secretory Protein 4 expressions were determined in both normal cervical epithelia and in intraepithelial carcinomas, while increased HE4 expression was observed in invasive tumors.
Conclusions: This study demonstrated that altered expression of Human Epididymal Secretory Protein 4 may involve in tumorigenesis in the uterine cervix. Our findings also suggested the presence of a correlation between Human Epididymal Secretory Protein 4 expression and the invasive potential of uterine tumors. Therefore it may be thought that the tissue expression of HE4 can be used to differentiate high grade intraepithelial tumors from carcinomas.
Keywords: Uterine cervixHuman Epididymal Secretory Protein 4HE4squamous cell carcinomaadenosquamous carcinomaadenocarcinoma
References
- Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991; 45(2): 350–357.
- Li J, Chen H, Mariani A, et al. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int J Mol Sci. 2013; 14(3): 6026–6043.
- Gündüz UR, Gunaldi M, Isiksacan N, et al. A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study. Mol Clin Oncol. 2016; 5(2): 355–360.
- Ferraro S, Schiumarini D, Panteghini M. Human epididymis protein 4: factors of variation. Clin Chim Acta. 2015; 438: 171–177.
- Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63(13): 3695–3700.
- Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847–853.
- Deng Lu, Gao Y, Li X, et al. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res. 2015; 34: 96.
- Kurman RJ, Ellenson LH, Ronnett BM. Bleustein’s Pathology of the Female Genital Tract. Sixth Ed. Springer 2011 New York.:286-287.
- Solakoglu Kahraman D, Diniz G, Sayhan S, et al. Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix. APMIS. 2015; 123(10): 847–850.
- Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol. 2000; 78(2): 97–105.
- Contag SA, Gostout BS, Clayton AC, et al. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004; 95(3): 610–617.
- Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65(6): 2162–2169.
- Piovano E, Attamante L, Macchi C, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014; 24(8): 1359–1365.
- Georgakopoulos P, Mehmood S, Akalin A, et al. Immunohistochemical localization of HE4 in benign, borderline, and malignant lesions of the ovary. Int J Gynecol Pathol. 2012; 31(6): 517–523.
- Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002; 21(17): 2768–2773.
- Yamashita SI, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol. 2011; 32(2): 265–271.
- Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol. 2012; 33(4): 1141–1149.
- Nozaki K, Ogawa M, Williams JA, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology. 2008; 134(2): 511–522.
- O'Neal RL, Nam KiT, LaFleur BJ, et al. Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Hum Pathol. 2013; 44(5): 734–742.
- Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000; 24(3): 227–235.
- Guo YD, Wang JH, Lu H, et al. The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer. Tumour Biol. 2015; 36(4): 2457–2464.
